QUOTE AND NEWS
Benzinga  May 14  Comment 
Forbes Energy Services Ltd. (NASDAQ: FES) shares gained 77.61 percent to $2.38. Forbes Energy reported a Q1 loss of $0.21 per share. Vascular Biogenics Ltd (NASDAQ: VBLT) shares rose 59.19 percent to $6.49. VBL Therapeutics reported that it...
Forbes  May 5  Comment 
In trading on Tuesday, drugs shares were relative laggards, down on the day by about 2.4%. Helping drag down the group were shares of AcelRx Pharmaceuticals (ACRX), down about 28.6% and shares of PTC Therapeutics (PTCT) down about 11.9% on the day.
FierceBiotech  May 5  Comment 
The battering that AcelRx has been subjected to on Wall Street won't stop. The biotech announced that the FDA won't even sit down to discuss regulators' demand for a new clinical trial to assess the efficacy of its pain drug/device Zalviso. And...
Benzinga  May 5  Comment 
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares fell 29.28 percent to reach a new 52-week low of $2.97 after the company reported Q1 GAAP loss of $0.27 per share and issued a Zalviso regulatory update. Zulily Inc (NASDAQ: ZU) shares dropped...
Benzinga  May 5  Comment 
Qualys Inc (NASDAQ: QLYS) shares dipped 25.34 percent to $41.12 after the company issued a downbeat outlook for the second quarter. AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) shares slipped 23.10 percent to $3.23 after the company reported Q1...
newratings.com  May 5  Comment 
DEERFIELD (dpa-AFX) - Shares of AcelRx Pharmaceuticals Inc. (ACRX) were down more than 27% in extended trading on Monday after the company revealed that its request for a Type B meeting with the FDA, to clarify the agency's belief that an...




 
TOP CONTRIBUTORS

AcelRx (NASDAQ:ACRX) is a pharmaceutical company which develops and sells treatments for acute and breakthrough pain. In particular, the product would help with post-operative pain. AcelRx has completed Phase 2 and is preparing to conduct two Phase 3 clinical trials for its lead product.[1]

Acute and breakthrough pain associated with the post-operation period is often treated with intravenous (IV) opioid injections. These tend to have negative side effects due to the usage of morphine. In addition, there can be delivery and programming errors from the complex infusion pumps used to provide the patients with the opioid. AcelRx's lead candidate involves a patient administered dosage sublingual, or below the tongue. AcelRx also uses Sufentanil rather than morphine.[2]

The company's initial public offering of stock on the NASDAQ occurred on February 10, 2011. The company offered 8M shares each for $5. The company originally planned to sell 5.8M shares within the range of $12-$14. This would have made the deal worth $75.4M, but the drop in price brought the total deal to $40M even after the rise in shares sold. The lead underwriter of the deal was Piper Jaffray Companies (PJC). Canaccord Capital (BER:C6U), Cowen Group (COWN), and JMP Group (JMP) acted as comanagers.[3]

Because AcelRx does not have a commercially viable yet, the company is still in the pre-revenue stage. As a result, the company has incurred high Research & Development expenses without making money. For the first 9 months of 2010, AcelRx's net loss was $10.8M, 58% of which was from research and development expenses. [4]

References

  1. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg1
  2. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Sufentanil NanoTabs" pg1-2
  3. Renaissance Capital - IPO Home "AcelRx prices IPO at $5, below the original $12-$14 range" 11 Feb 2011
  4. ACRX S-1/A 2011 PROSPECTUS SUMMARY "Summary Financial Data" pg10
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki